Vir Biotechnology (VIR) Research & Development (2018 - 2026)

Vir Biotechnology has reported Research & Development for 9 years, with the latest figure at $108.9 million in Q1 2026.

• Quarterly Research & Development fell 8.2% year-over-year to $108.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $446.2 million (down 15.0% YoY) and the FY2025 annual result came in at $456.0 million, down 9.98% from the prior year.
• Research & Development improved to $108.9 million in Q1 2026 per VIR's latest filing, from $88.3 million in the prior quarter.
• Over five years, Research & Development peaked at $195.2 million in Q3 2024 and troughed at $88.3 million in Q4 2025.
• A 5-year average of $125.0 million and a median of $114.2 million in 2022 frame the typical range for Research & Development.
• The sharpest annual moves came in 2023 and 2024: Research & Development jumped 74.72% in 2023, then sank 37.46% in 2024.
• Over 5 years, Research & Development stood at $155.2 million in 2022, then declined by 29.78% to $109.0 million in 2023, then decreased by 2.65% to $106.1 million in 2024, then slipped by 16.72% to $88.3 million in 2025, then gained by 23.29% to $108.9 million in 2026.
• According to Business Quant data, Research & Development over the past three periods registered $108.9 million, $88.3 million, and $151.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.